MarketInOut Stock Screener Log In | Sign Up
 

Calidi Biotherapeutics Inc

NYSE • Healthcare • Biotechnology • Quote as of 09/11/2026
Calidi Biotherapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization3.49 mln
Float2.56 mln
Earnings Date11/13/2026

Piotroski F-Score

3 / 9
Below average

Relative Strength

29 / 100
Underperforming

Debt / Equity

0.62
Moderate leverage

ROE

-426
Deeply negative

Dividend Yield

0.00%
No dividend

DPS

0.00
No dividend

Business Description

Founded in 2014 and based in San Diego, California, Calidi Biotherapeutics is a clinical-stage company focused on using stem cells to deliver cancer-fighting viruses directly to tumors. Its most advanced treatment, CLD-101, is currently being tested in clinical trials for patients with high-grade brain cancer, while several other therapies targeting solid tumors and lung cancer are in earlier stages of development. The company's approach is built around proprietary platforms designed to make these viral treatments more effective and better tolerated by patients.

Key Fundamentals

EPS-37.04
ROE-426
ROIC-375
ROA-178
EBITDA, mln-15.62
EV / EBITDA-0.08
EV / EBIT-0.07

Financial Strength

Piotroski F-Score 3 / 9
Short Ratio0.73
Short % of Float12.22

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -8.15% 12 / 100   
1 Month -23.93% 8 / 100   
2 Months -53.21% 6 / 100   
6 Months -77.62% 3 / 100   
1 Year -95.3% 3 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us